Study Summary
A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Want to learn more about this trial?
Request More InfoInterventions
PRG2302DRUG
Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First People's Hospital of Jingzhou | Jinzhou | Hubei | China |